Tetracycline is more preferred in periodontics because:
Which anti-tubercular drug combination is safer in a patient who develops hepatitis while on ATT?
Which antitubercular drug inhibits mycolic acid synthesis?
Which of the following drugs acts by inhibiting bacterial protein synthesis?
All of the following are bactericidal except?
What is the drug of choice for Clostridium difficile infection?
A 25-year-old male hospitalized with a liver cyst due to Echinococcus granulosis refused surgery. Albendazole was administered at a high dose for 3 months. For which organ's toxicity should this patient be monitored?
Cross-resistance to macrolides occurs primarily due to which of the following mechanisms?
The Eagle effect is observed in which of the following microorganisms?
What is the drug of choice for Plasmodium vivax?
Explanation: Tetracyclines (specifically Doxycycline and Minocycline) are the drugs of choice in periodontics due to their unique dual-action mechanism [2]:1. **Antimicrobial Action (Broad-spectrum):** Periodontitis is a polymicrobial infection involving Gram-negative anaerobes (e.g., *Aggregatibacter actinomycetemcomitans*). Tetracyclines are broad-spectrum bacteriostatic agents that inhibit protein synthesis (30S subunit), effectively reducing the subgingival bacterial load [1].2. **Anticollagenolytic Effect (Non-antimicrobial):** This is the high-yield clinical reason for their preference. Tetracyclines inhibit **Matrix Metalloproteinases (MMPs)**, specifically **collagenase**, which is responsible for the destruction of the periodontal ligament and alveolar bone. By inhibiting these enzymes, tetracyclines promote tissue attachment and reduce bone resorption, independent of their antibacterial effect.**Analysis of Options:** * **Option A:** Correct, as its broad-spectrum nature covers the primary pathogens involved in periodontal disease [2].* **Option B:** Correct, as the inhibition of collagenase is a unique host-modulatory property that prevents tissue destruction.* **Option C (All of the above):** Since both A and B are significant therapeutic advantages in treating periodontitis, this is the most appropriate choice.**High-Yield Clinical Pearls for NEET-PG:** * **Periostat:** A sub-antimicrobial dose of Doxycycline (20 mg BID) is FDA-approved specifically for its **anticollagenolytic effect** in chronic periodontitis, minimizing side effects and resistance.* **Concentration:** Tetracyclines achieve concentrations in the **gingival crevicular fluid (GCF)** that are 2–10 times higher than in serum.* **Side Effects:** Remember the "T"s: **T**eratogenic, **T**eeth discoloration (avoid in children <8 years), and **T**oxicity (Phototoxicity and Hepatotoxicity) [2].
Explanation: **Explanation:** The primary concern when managing a patient who develops drug-induced hepatitis during Anti-Tubercular Therapy (ATT) is to avoid further hepatotoxicity. **1. Why Streptomycin + Ethambutol is correct:** Among the first-line ATT drugs, **Isoniazid (H), Rifampicin (R), and Pyrazinamide (Z)** are known to be hepatotoxic [1]. In contrast, **Ethambutol (E) and Streptomycin (S)** are non-hepatotoxic drugs. When a patient develops clinical jaundice or a significant rise in liver enzymes (ALT/AST >3x with symptoms or >5x without symptoms), all hepatotoxic drugs must be stopped immediately. A safe "non-hepatotoxic" regimen consisting of Streptomycin and Ethambutol is initiated until the liver functions normalize. **2. Why the other options are incorrect:** * **Options A & C:** Both contain **Isoniazid (H)**, which is a potent hepatotoxin (via its metabolic pathway) [1]. * **Option D:** Contains **Rifampicin (R)**, which can cause cholestatic jaundice and potentiate the toxicity of other drugs [1]. Since these options contain at least one hepatotoxic agent, they are unsafe during the acute phase of hepatitis. **Clinical Pearls for NEET-PG:** * **Hepatotoxicity Order:** The most hepatotoxic drug is **Pyrazinamide**, followed by **Isoniazid**, and then **Rifampicin** (Z > H > R) [1]. * **Management Protocol:** Once the AST/ALT levels return to <2x the upper limit of normal, hepatotoxic drugs are reintroduced one by one (usually Rifampicin first, then Isoniazid, then Pyrazinamide). * **Safe in Liver Disease:** Streptomycin, Ethambutol, and Fluoroquinolones (like Levofloxacin) are the preferred agents when the standard HRZE regimen cannot be used due to liver dysfunction [1].
Explanation: ### Explanation **Correct Answer: A. Isoniazid** **Mechanism of Action:** Isoniazid (INH) is a prodrug activated by the mycobacterial enzyme **KatG** (catalase-peroxidase). [3] Once activated, it inhibits the enzyme **InhA** (enoyl-acyl carrier protein reductase), which is essential for the synthesis of **mycolic acids**. [3] Mycolic acids are long-chain fatty acids that are unique and vital components of the mycobacterial cell wall. Inhibition leads to the disruption of the cell wall, making INH bactericidal against rapidly dividing organisms. **Why other options are incorrect:** * **Streptomycin:** An aminoglycoside that acts by binding to the **30S ribosomal subunit**, thereby inhibiting bacterial protein synthesis. It is bactericidal but does not affect the cell wall. * **Rifampicin:** Inhibits **DNA-dependent RNA polymerase**, preventing the transcription of DNA into mRNA. [1] It is a key bactericidal drug in the RNTCP regimen. * **Ethambutol:** Inhibits the enzyme **arabinosyl transferase**, which prevents the synthesis of **arabinogalactan**, another essential component of the mycobacterial cell wall. It is bacteriostatic. **High-Yield Clinical Pearls for NEET-PG:** * **Resistance:** Most commonly due to the deletion or mutation of the **KatG gene**. [2] * **Side Effects:** Peripheral neuropathy (due to Vitamin B6/Pyridoxine deficiency) and Hepatotoxicity (the most common side effect). * **Metabolism:** INH is metabolized via **Acetylation**. [3] "Slow acetylators" are at a higher risk of developing peripheral neuropathy. * **Prophylaxis:** INH is the drug of choice for Latent TB and for chemoprophylaxis in contacts of open TB cases.
Explanation: **Explanation:** The correct answer is **Streptomycin**. Streptomycin is an **Aminoglycoside** antibiotic that acts by binding to the **30S ribosomal subunit** of bacteria. This binding causes misreading of the mRNA code and inhibits the initiation of protein synthesis, leading to a bactericidal effect. **Analysis of Options:** * **A. Bacitracin:** This drug inhibits **cell wall synthesis** by interfering with the dephosphorylation of the lipid carrier (bactoprenol) that transports peptidoglycan precursors across the cell membrane. * **B. Dapsone:** This is a sulfonamide-like drug used in leprosy. It inhibits the enzyme **dihydropteroate synthase**, thereby blocking **folic acid synthesis**. * **C. Ethambutol:** An antitubercular drug that inhibits **arabinosyltransferase**, an enzyme essential for the synthesis of **arabinogalactan** in the mycobacterial cell wall. **High-Yield Clinical Pearls for NEET-PG:** * **Protein Synthesis Inhibitors Mnemonic:** * **30S inhibitors:** **A**minoglycosides (Streptomycin, Gentamicin), **T**etracyclines (**"AT 30"**). * **50S inhibitors:** **C**hloramphenicol, **E**rythromycin (Macrolides), **L**inezolid, **L**incosamides (Clindamycin) (**"CELL at 50"**). * **Streptomycin Specifics:** It is the only aminoglycoside used as a first-line drug for Tuberculosis (though now often replaced by oral regimens). Its major side effects are **ototoxicity** (vestibular damage) and **nephrotoxicity**. * **Ethambutol** is unique among first-line ATT for causing **optic neuritis** (red-green color blindness).
Explanation: ### Explanation The classification of antibiotics into **bactericidal** (kill bacteria) and **bacteriostatic** (inhibit growth) is a high-yield concept for NEET-PG. **1. Why Oxytetracycline is the correct answer:** Oxytetracycline belongs to the **Tetracycline** class. These agents act by reversibly binding to the **30S ribosomal subunit**, inhibiting protein synthesis. Because the binding is reversible and only halts the multiplication of bacteria without immediate cell death, they are classified as **bacteriostatic**. **2. Why the other options are incorrect:** * **Cephalexin (Option A):** This is a first-generation cephalosporin. Like all beta-lactams, it inhibits cell wall synthesis by binding to Penicillin-Binding Proteins (PBPs), leading to cell lysis. It is **bactericidal**. * **Rifampicin (Option B):** It inhibits DNA-dependent RNA polymerase. By blocking the transcription of essential RNA, it causes rapid bacterial death. It is a potent **bactericidal** drug. * **Isoniazid (Option C):** It inhibits the synthesis of mycolic acids, essential components of the mycobacterial cell wall. It is **bactericidal** against rapidly dividing *M. tuberculosis* (though it can be bacteriostatic against resting organisms). **3. Clinical Pearls & High-Yield Facts:** * **Mnemonic for Bactericidal drugs:** "**V**ery **F**inely **P**roficient **A**t **C**ell **M**urder" (**V**ancomycin, **F**luoroquinolones, **P**enicillins/Beta-lactams, **A**minoglycosides, **C**otrimoxazole, **M**etronidazole). * **Exception:** Aminoglycosides are the only major class of protein synthesis inhibitors that are **bactericidal** (irreversible binding). * **Antagonism:** Generally, bacteriostatic drugs (like Tetracyclines) should not be combined with bactericidal drugs (like Penicillins) because bactericidal drugs require the bacteria to be actively dividing to be effective.
Explanation: **Explanation:** **1. Why Vancomycin is the Correct Answer:** According to the latest clinical guidelines (IDSA/SHEA), **Oral Vancomycin** is now considered the first-line drug of choice for both initial and recurrent episodes of *Clostridium difficile* infection (CDI). The underlying medical concept is its pharmacokinetics: when administered orally, Vancomycin is poorly absorbed from the GI tract, leading to high intraluminal concentrations directly at the site of infection with minimal systemic toxicity [1]. **2. Why the Other Options are Incorrect:** * **Metronidazole:** Previously the drug of choice for mild-to-moderate CDI, it is now relegated to an alternative agent only when Vancomycin or Fidaxomicin are unavailable, due to increasing treatment failure rates [2]. It remains indicated for CDI and is administered 500 mg orally or intravenously [3]. * **Ceftriaxone:** This is a third-generation cephalosporin. It is not effective against *C. difficile* and is actually a common **precipitating factor** for the infection because it disrupts normal gut flora. * **Clindamycin:** This is notoriously associated with **causing** *C. difficile* associated diarrhea (pseudomembranous colitis) by suppressing the protective anaerobic flora of the colon. **3. NEET-PG High-Yield Clinical Pearls:** * **Fidaxomicin:** A macrocyclic antibiotic that is also a first-line agent (often preferred over Vancomycin if available) because it has a narrower spectrum and lower recurrence rates. * **Route of Administration:** For CDI, Vancomycin must be given **orally** [1]. IV Vancomycin is ineffective as it does not reach the gut lumen in therapeutic concentrations. * **Fulminant CDI:** For severe, complicated cases (hypotension/ileus), the treatment is a combination of high-dose oral Vancomycin and IV Metronidazole. * **Bezlotoxumab:** A monoclonal antibody against *C. difficile* toxin B, used to prevent recurrence.
Explanation: **Explanation:** The correct answer is **Liver (Option C)**. **Underlying Medical Concept:** Albendazole is a benzimidazole carbamate used as the drug of choice for Hydatid disease (*Echinococcus granulosus*). While it is generally well-tolerated for short-term use (e.g., 1–3 days for intestinal worms), **prolonged high-dose therapy** required for systemic infections like liver cysts necessitates strict monitoring. Albendazole is extensively metabolized in the liver to its active metabolite, albendazole sulfoxide. Long-term administration is frequently associated with a transient rise in serum transaminases (ALT/AST) and, in some cases, severe hepatotoxicity or jaundice. Therefore, Liver Function Tests (LFTs) must be monitored at the start of each treatment cycle and every two weeks during therapy. **Analysis of Incorrect Options:** * **A. Gonads:** While some benzimidazoles showed teratogenic potential in animal studies (hence avoided in pregnancy), they are not typically associated with gonadal toxicity or infertility in humans. * **B. Kidney:** Albendazole is primarily eliminated via biliary excretion; renal impairment is not a common side effect, and routine monitoring of renal function is not mandatory for this drug. * **D. Peripheral nerves:** Neurotoxicity is not a recognized side effect of albendazole. Peripheral neuropathy is more commonly associated with drugs like Isoniazid, Ethambutol, or Vincristine. **High-Yield NEET-PG Pearls:** * **Mechanism of Action:** Inhibits microtubule synthesis by binding to **β-tubulin**, leading to glucose depletion and death of the parasite. * **Monitoring:** Besides LFTs, **Complete Blood Counts (CBC)** should be monitored due to the risk of bone marrow suppression (leukopenia/pancytopenia) during long-term use. * **Absorption:** Oral absorption is significantly **increased with a fatty meal** (crucial for systemic infections like Hydatid disease or Neurocysticercosis).
Explanation: ### Explanation **1. Why Option C is Correct:** The most common and clinically significant mechanism of resistance to macrolides (like Erythromycin and Azithromycin) is **ribosomal protection**. This occurs via the production of an enzyme called **methylase**, encoded by the **_erm_ gene** (Erythromycin Ribosome Methylation). This enzyme methylates a specific adenine residue on the **23S rRNA** of the **50S ribosomal subunit**. This structural modification reduces the binding affinity of the drug to its target site. Because Macrolides, Lincosamides (Clindamycin), and Streptogramin B share overlapping binding sites, this mechanism leads to **cross-resistance** among all three classes, a phenomenon known as **MLS_B resistance**. **2. Why Other Options are Incorrect:** * **Option A (Efflux Pump):** While efflux pumps (encoded by the _mef_ gene) do exist and contribute to resistance (especially in *S. pneumoniae*), they typically result in lower levels of resistance and do not usually cause the broad cross-resistance seen with ribosomal methylation. * **Option B (Hydrolyzing Enzymes):** Enzymatic inactivation (e.g., by esterases) is a rare mechanism of resistance for macrolides, primarily seen in certain Gram-negative bacteria like *Enterobacteriaceae*, but it is not the primary cause of cross-resistance. **3. NEET-PG High-Yield Pearls:** * **MLS_B Phenotype:** If a lab report shows resistance to Erythromycin, always check for Clindamycin resistance (the **D-test** is used to detect inducible Clindamycin resistance). * **Mechanism of Action:** Macrolides are bacteriostatic; they inhibit protein synthesis by binding to the 50S subunit and preventing **translocation**. * **Drug of Choice:** Macrolides are the preferred alternative for Penicillin-allergic patients with Streptococcal infections and are the first-line treatment for **Atypical Pneumonia** (*Mycoplasma, Legionella*).
Explanation: ### Explanation The **Eagle Effect** (also known as the paradoxical zone phenomenon) refers to a situation where the efficacy of an antimicrobial agent decreases as the concentration of the drug increases beyond a specific threshold. **1. Why Enterococcus faecalis is correct:** The Eagle effect is classically associated with **Enterococcus faecalis** when treated with **Penicillins** (like Ampicillin). At optimal concentrations, penicillins are bactericidal; however, at very high concentrations, the rate of bacterial killing paradoxically decreases. This occurs because high doses of penicillin can inhibit protein synthesis or lead to a "stasis" in bacterial growth. Since beta-lactams require actively dividing cells to exert their bactericidal effect (by inhibiting cell wall synthesis), this induced dormancy makes the bacteria less susceptible to the drug. **2. Analysis of Incorrect Options:** * **Staphylococcus aureus:** While some strains may show reduced killing at high concentrations, it is not the classic organism used to describe this effect in medical pharmacology textbooks. * **Pseudomonas aeruginosa:** Resistance in Pseudomonas is typically due to efflux pumps, porin loss, or beta-lactamases, rather than the paradoxical Eagle effect. * **Streptococcus pyogenes:** While Harry Eagle originally described this phenomenon in *S. pyogenes* in vitro (the "prozone" effect), in the context of NEET-PG and standard pharmacology references (like K.D. Tripathi), the clinical relevance is most frequently highlighted for **Enterococci**. **3. High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** High drug concentrations lead to the downregulation of Penicillin-Binding Proteins (PBPs), specifically those involved in cell wall autolysis. * **Clinical Significance:** This effect is one reason why **combination therapy** (e.g., Ampicillin + Gentamicin) is preferred for Enterococcal endocarditis to ensure synergistic bactericidal action. * **Post-Antibiotic Effect (PAE):** Do not confuse the Eagle effect with PAE (persistent suppression of bacterial growth after drug exposure), which is most prominent with Aminoglycosides and Fluoroquinolones.
Explanation: **Explanation:** **Chloroquine (Option B)** remains the **Drug of Choice (DOC)** for the treatment of the erythrocytic stage of *Plasmodium vivax* in areas where the parasite remains sensitive. It is a rapidly acting blood schizonticide that interferes with heme detoxification within the parasite's food vacuole. However, for a "radical cure" (prevention of relapse), it must be followed by **Primaquine** for 14 days to eradicate the latent liver stages (hypnozoites). **Analysis of Incorrect Options:** * **Mefloquine (Option A):** Primarily used for prophylaxis in travelers or as a treatment for chloroquine-resistant *P. falciparum*. It is not the first-line choice for *P. vivax* due to its side effect profile (neuropsychiatric issues). * **Artesunate (Options C & D):** This is an Artemisinin derivative and is the **DOC for Severe/Complicated Malaria** (regardless of species) and for uncomplicated *P. falciparum* (as part of ACT). While effective against *P. vivax*, it is reserved for resistant cases or severe presentations to prevent the development of resistance. **High-Yield Clinical Pearls for NEET-PG:** 1. **DOC for Uncomplicated *P. falciparum*:** Artemisinin-based Combination Therapy (ACT). 2. **DOC for Severe Malaria:** Intravenous (IV) Artesunate. 3. **DOC for Malaria in Pregnancy:** Chloroquine (1st, 2nd, and 3rd trimester) if sensitive; Quinine + Clindamycin is used for resistant cases in the 1st trimester. 4. **Primaquine Caution:** Always screen for **G6PD deficiency** before administration to avoid acute hemolysis. It is strictly contraindicated in pregnancy. 5. **Relapse vs. Recrudescence:** *P. vivax* and *P. ovale* cause **relapse** (from liver hypnozoites); *P. falciparum* causes **recrudescence** (from persistent blood stages).
Beta-Lactam Antibiotics
Practice Questions
Aminoglycosides
Practice Questions
Macrolides and Ketolides
Practice Questions
Tetracyclines
Practice Questions
Quinolones
Practice Questions
Sulfonamides and Trimethoprim
Practice Questions
Antimycobacterial Drugs
Practice Questions
Antifungal Agents
Practice Questions
Antiviral Drugs
Practice Questions
Antiparasitic Agents
Practice Questions
Principles of Antimicrobial Selection
Practice Questions
Antimicrobial Resistance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free